drugset
drugset / Trial / NCT02857361

Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.

NCT02857361 ↗

Phase 2 Completed 10 enrolled iX Biopharma Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The study will look at whether it is preferable to administer two wafers simultaneously or separately.

Timeline

Start
2016-07
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 50 mg Other

Indications

No indication recorded.